

Advances in Lung Gancer





Journal Editorial Board

http://www.scirp.org/journal/alc

.....

Editor-in-Chief

Prof. William N. Rom New York University School of Medicine, USA

Editorial Board

Dr. Seema Agarwal Yale University School of Medicine, USA

Dr. Dharani Kumar Ajithdoss Texas A&M University, USA

Dr. Krishna Balasubramanian University of Pittsburgh, USA

Dr. Raj K. Batra David Geffen School of Medicine at UCLA, USA

Dr. Darren Michael Riehl Brenner International Agency for Research on Cancer, Canada

Prof. Carmen Wing Han Chan-Yip The Chinese University of Hong Kong, China

Dr. Guoan Chen The University of Michigan, USA

Dr. Salwa El-Sobkey King Saud University, Saudi Arabia

Dr. Weimin Gao Texas Tech University, USA

Dr. Jennifer L. Garst Duke Raleigh Cancer Center, USA

Prof. James Chung-man Ho University of Hong Kong, China

Dr. Walid E. Khalbuss University of Pittsburgh Medical Center (UPMC), USA

Dr. Percy P. Lee David Geffen School of Medicine at UCLA, USA

Dr. R. Charles NicholsUniversity of Florida Proton Therapy Institute, USA

Dr. Shahla Ray Indiana University, USA

Prof. Sherven Sharma University of California at Los Angeles, USA

Dr. Ranjita Shegokar Free University of Berlin, Germany

Dr. Wenjie Sun

Guangdong Pharmaceutical University, China

Dr. Kostas Syrigos

Athens University School of Medicine, Greece

Dr. John Michael VarlottoPenn State University, USA

Dr. Jeng-Shing Wang Antai Tian-Sheng Memorial Hospital & Taipei Medical University, China

Dr. Xiaofei Wang Duke University Medical Center, USA

Dr. Moges Woldemeskel University of Georgia, USA



Table of Contents

Volume 3	Number 1	March 2014
•	dy for Biweekly Administration of Cisplatin plus y Resected Non-Small Cell Lung Cancer Patients	
S. Tsukamoto	o, K. Yamazaki, R. Mori, M. Katsura, H. Kouso, D. Kawa	ano, C. Ushijima, S. Takeo1
A Phase II Stud	dy of Erlotinib in Patients with Previously Treat	ed Non-Small Cell Lung Cancer
•	Okano, M. Sakai, T. Yamane, N. Shiota, H. Ohnishi, H.	•
Five-Year Surv	vivors of Non-Small Cell Lung Cancer Patients wi	th Positive Pleural Lavage Cytology
M. Tomita, T.	. Ayabe, E. Chosa, K. Nakamura	21
•	Regression Model for Forecasting of Survival Ra Cell Lung Cancer	te in Patients with the Early Stage
O. P. Kolesnik	k, A. I. Shevchenko, Y. E. Lyakh, V. G. Gurianov, P. A. A	Alyoshechkin26

Advances in Lung Cancer (ALC)

Journal Information

SUBSCRIPTIONS

The *Advances in Lung Cancer* (Online at Scientific Research Publishing, www.SciRP.org) is published quarterly by Scientific Research Publishing, Inc., USA.

Subscription rates:

Print: \$59 per issue.

To subscribe, please contact Journals Subscriptions Department, E-mail: sub@scirp.org

SERVICES

Advertisements

Advertisement Sales Department, E-mail: service@scirp.org

Reprints (minimum quantity 100 copies)

Reprints Co-ordinator, Scientific Research Publishing, Inc., USA.

E-mail: sub@scirp.org

COPYRIGHT

COPYRIGHT AND REUSE RIGHTS FOR THE FRONT MATTER OF THE JOURNAL:

Copyright © 2014 by Scientific Research Publishing Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/

COPYRIGHT FOR INDIVIDUAL PAPERS OF THE JOURNAL:

Copyright $\ensuremath{\mathbb{Q}}$ 2014 by author(s) and Scientific Research Publishing Inc.

REUSE RIGHTS FOR INDIVIDUAL PAPERS:

Note: At SCIRP authors can choose between CC BY and CC BY-NC. Please consult each paper for its reuse rights.

DISCLAIMER OF LIABILITY

Statements and opinions expressed in the articles and communications are those of the individual contributors and not the statements and opinion of Scientific Research Publishing, Inc. We assume no responsibility or liability for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained herein. We expressly disclaim any implied warranties of merchantability or fitness for a particular purpose. If expert assistance is required, the services of a competent professional person should be sought.

PRODUCTION INFORMATION

For manuscripts that have been accepted for publication, please contact:

E-mail: alc@scirp.org





Advances in Lung Cancer

ISSN Print: 2169-2718 ISSN Online: 2169-2726

http://www.scirp.org/journal/alc

Advances in Lung Cancer (ALC) is a peer-reviewed, open access journal published quarterly. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in all aspects of basic and clinical lung cancer research.

Subject Coverage

All manuscripts must be prepared in English, and are subject to a rigorous peer-review process. Accepted papers will immediately appear online followed by printed in hard copy. The areas covered by Advances in Lung Cancer (ALC) include but are not limited to the following fields:

- Angiogenesis and Tumor Invasion
- Basic Biology of Lung Cancer
- Clinical Assessment of Lung Cancer
- Detection and Screening of Lung Cancer
- Epidemiology and Etiology of Lung Cancer
- Lung Cancer Chemotherapy
- Lung Cancer Radiotherapy
- Lung Cancer Staging
- Lung Cancer Surgery
- Non-Small-Cell Lung Carcinomas (NSCLC)
- Pancoast Tumors
- Pathology of Lung Cancer
- Prevention of Lung Cancer
- Small-Cell Lung Carcinoma (SCLC)
- Symptoms of Lung Cancer

We are also interested in: 1) Short reports—2-5 page papers where an author can either present an idea with theoretical background but has not yet completed the research needed for a complete paper or preliminary data; 2) Book reviews—Comments and critiques.

Website and E-mail

http://www.scirp.org/journal/alc E-mail: alc@scirp.org